From: Maintenance therapy in NSCLC: why? To whom? Which agent?
Trial/Author | Comparison | Comments | References |
---|---|---|---|
NCT01107626 ECOG 5508 | Paclitaxel/Carboplatin/Bevacizumab, followed by pemetrexed vs bevacizumab vs pemetrexed/bevacizumab | not yet open for recruitment | [39] |
NCT00789373 Paz-Ares LG | Maintenance Pemetrexed/BSC Vs BSC Immediately Following Induction Treatment With Pemetrexed + Cisplatin for Advanced Nonsquamous NSCLC | currently recruiting | [39] |
NCT00762034 Patel et al. | Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab vs Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in IIIB or IV Nonsquamous NSCLC | currently recruiting | [39] |
NCT00820755 NEXT | Platinum-based chemotherapy plus cetuximab followed by cetuximab as maintenance with either 500 mg/m2 every 2 w or 250 mg/m2 every w | ongoing, not recruiting | [39] |
NCT00948675 Zinner et al. | Pemetrexed/carboplatin with maintenance pemetrexed vs paclitaxel/carboplatin/bevacizumab with maintenance bevacizumab in IIIB or IV Nonsquamous NSCLC | currently recruiting | [39] |
NCT00693992 CALGB 30607 | Sunitinib as maintenance therapy vs placebo in Non-Progressing Patients Following 4 Cycles of Platinum-Based Combination in IIIB/IV NSCLC | currently recruiting | [39] |
NCT00961415 AVAPERL1 | Bevacizumab with or without pemetrexed as maintenance after 4 cycles Bevacizumab/Cisplatin/Pemetrexed | currently recruiting | [39] |
NCT00676507 STOP | Lucanix™ (Belagenpumatucel-L) as Maintenance III/IV NSCLC with SD or PR and Who Have Responded to or Have Stable Disease Following One Regimen of Front-line, Platinum-based Combination Chemotherapy | currently recruiting | [39] |